Оценка эффективности применения модифицирующей терапии (комплекса VERIS (пектин + инулин) с солевым энтеральным раствором) у пациентов с язвенным колитом

Abstract

Purpose: to evaluate the effect of the use of modifying therapy (VERIS complex (Pectin + Inulin) in combination with saline enteral solution) on the effectiveness of treatment of patients with moderate ulcerative colitis (UC). Material and methods. A comparative clinical study was conducted with active effects on the observed group. This study included men and women with a moderate attack of ulcerative colitis without severe concomitant pathology and signs of reactivation of an opportunistic infection. Using a continuous sampling method, 45 patients (n = 45) aged 32 ± 7.5 years were selected who were undergoing inpatient treatment in the gastroenterological department of the State Budgetary Healthcare Institution “Research Institute-KKB No. 1” named after Professor S.V. Ochapovsky regarding inflammatory bowel diseases (IBD). Depending on the chosen treatment strategy, all patients were divided into 3 groups: group 1 included patients who, in addition to basic therapy for IBD, received VERIS (pectin + inulin) (n = 15), group 2 included patients receiving only basic therapy (n = 15), the third group included patients who, in addition to the main therapy, received the combination of VERIS (pectin + inulin) + SER (n = 15). In the groups, a comparative assessment of the volume of the lesion, symptoms of the disease, such as pain, fever, tenesmus, stool frequency and the presence of blood in it, as well as the results of laboratory tests, including data from the blood flow rate, ESR, CRP, blood electrolyte composition, nitrogenous wastes, were carried out and liver transaminases, albumin and indicators of electrolyte metabolism (K, Na, Cl). The dynamics of the above-described indicators in each of the groups was also assessed at 3 stages of observation: initially, on the 5th and 10th day of treatment. In addition to the listed parameters, in both groups the duration of hospitalization in bed days, the level of quality of life (IBDQ questionnaire), and the degree of psycho-emotional disorders according to the HADS hospital anxiety and depression scale were assessed. Results. It was found that when the combination VERIS (Pectin + Inulin) was included in the basic therapy in combination with saline enteral solution, a decrease in the activity of the systemic inflammatory process was revealed, which was manifested by positive dynamics of leukocytosis, a decrease in the average erythrocyte sedimentation rate, and an increase in hemoglobin levels. A statistically significant decrease in cytolysis markers (decrease in liver transaminases) and catabolism indicators was also noted, which was reflected in the form of a decrease in the level of nitrogenous wastes. It should be noted that no undesirable side effects or allergic reactions were registered during the study period. The revealed reduction in the length of hospitalization of patients in the group receiving VERIS (pectin + inulin) + SER, an increase in adherence to therapy due to an increase in the quality of life due to the rapid regression of symptoms can be regarded as significant indicators of the effectiveness of the therapy. The above results obtained by us indicate the modifying effect of the complex of enteroprotective drugs on the standard basic therapy of ulcerative colitis. Conclusion. The addition of the enteroprotective combination VERIS (pectin + inulin) in combination with saline enteral solution to the standard therapy of patients with moderate ulcerative colitis increases the effectiveness of treatment results by reducing the inflammatory process, the phenomena of cytolysis, catabolism and, as a consequence, leads to a decrease in hospitalization time, an increase in quality of life. All of the above allows us to consider this combination of drugs with the function of enteroprotection VERIS (pectin + inulin) + SER as a promising way to modify the basic therapy of inflammatory bowel diseases by compensating for intestinal failure during the treatment period.